Consun Pharmaceutical Group Limited (HKG:1681)

Market Cap	15.22B +133.4%
Revenue (ttm)	3.58B +19.3%
Net Income	1.11B +20.6%
EPS	1.29 +14.0%
Shares Out	841.31M
PE Ratio	14.02
Forward PE	11.48
Dividend	0.66 (3.67%)
Ex-Dividend Date	Sep 4, 2025

Volume	1,012,000
Average Volume	1,591,492
Open	18.00
Previous Close	18.00
Day's Range	17.75 - 18.14
52-Week Range	7.61 - 18.65
Beta	0.61
RSI	59.61
Earnings Date	Mar 23, 2026

About HKG:1681

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function ass...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 3,073
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1681

Financial Performance

In 2024, HKG:1681's revenue was 2.97 billion, an increase of 14.56% compared to the previous year's 2.59 billion. Earnings were 910.46 million, an increase of 16.05%.

Financial numbers in CNY